Theresa Graalmann Selected Research

Melanoma (Melanoma, Malignant)

3/2019

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Theresa Graalmann Research Topics

Disease

2	COVID-19 04/2024 - 12/2020
1	Convalescence 04/2024
1	Prolidase Deficiency 12/2023
1	Cytomegalovirus Infections (Inclusion Disease) 12/2023
1	Vasculitis (Vasculitides) 12/2023
1	Rheumatoid Arthritis 12/2021
1	Human Influenza (Influenza) 12/2021
1	Lymphoma (Lymphomas) 12/2021
1	Autoimmune Diseases (Autoimmune Disease) 12/2021
1	Infections 12/2021
1	Tuberculosis (Tuberculoses) 10/2021
1	Severe Acute Respiratory Syndrome 12/2020
1	Melanoma (Melanoma, Malignant) 03/2019
1	Inflammation (Inflammations) 01/2019

Drug/Important Bio-Agent (IBA)

2	Rituximab (Mabthera)FDA Link 12/2023 - 12/2021
2	VaccinesIBA 12/2021 - 03/2019
1	Immunoglobulins (Immunoglobulin)IBA 04/2024
1	AntibodiesIBA 04/2024
1	SteroidsIBA 12/2023
1	Antirheumatic Agents (DMARD)IBA 12/2023
1	proline dipeptidase (prolidase)IBA 12/2023
1	influvacIBA 12/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2021
1	Immunoglobulin G (IgG)IBA 12/2020
1	ImmunosorbentsIBA 12/2020
1	EnzymesIBA 12/2020
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 01/2019